{"id":3264,"date":"2007-02-12T11:09:53","date_gmt":"2007-02-12T09:09:53","guid":{"rendered":"http:\/\/www.ced.org.tr\/?p=3264"},"modified":"2007-02-12T11:09:53","modified_gmt":"2007-02-12T09:09:53","slug":"ilac-sirketleri-sanik-sandalyesinde","status":"publish","type":"post","link":"http:\/\/www.ced.org.tr\/?p=3264","title":{"rendered":"\u0130LA\u00c7 \u015e\u0130RKETLER\u0130 SANIK SANDALYES\u0130NDE"},"content":{"rendered":"

30 \u0130LA\u00c7 \u015e\u0130RKET\u0130 \u00c7ETE SU\u00c7LAMASIYLA SANIK SANDALYES\u0130NDE<\/h3>\n

\u0130stanbul Cumhuriyet Ba\u015fsavc\u0131l\u0131\u011f\u0131 aralar\u0131nda Roche, Abdi \u0130brahim, Bayer, Glaxo Smith Klein ve Pfizer’\u0131n oldu\u011fu 30 ila\u00e7 \u015firketine kamuya y\u00fcksek fiyatla ila\u00e7 satt\u0131klar\u0131 iddias\u0131yla dava a\u00e7t\u0131.
Sosyal Sigortalar Kurumu (SSK) ve Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’na y\u00fcksek fiyattan ila\u00e7 satt\u0131\u011f\u0131 gerek\u00e7esiyle dava a\u00e7\u0131lan Roche \u0130la\u00e7’\u0131n ard\u0131ndan 29 ila\u00e7 \u015firketine daha “\u00e7ete” olu\u015fturmak su\u00e7undan davas\u0131 a\u00e7\u0131ld\u0131. Roche davas\u0131 sonras\u0131nda ge\u00e7en y\u0131l harekete ge\u00e7en \u0130stanbul Cumhuriyet Ba\u015fsavc\u0131l\u0131\u011f\u0131’n\u0131n 30 \u015firket aleyhine ba\u015flatm\u0131\u015f oldu\u011fu soru\u015fturma \u00f6nceki g\u00fcn tamamland\u0131. Aralar\u0131nda Roche, Abdi \u0130brahim, Bayer, Glaxo Smith Klein, Pfizer’\u0131n oldu\u011fu 30 \u015firkete kamuya usuls\u00fcz olarak y\u00fcksek fiyatla ila\u00e7 satma iddias\u0131yla dava a\u00e7\u0131ld\u0131. Savc\u0131l\u0131\u011f\u0131n iddianamesinde san\u0131k olarak g\u00f6sterilen \u015firketlere “Su\u00e7 i\u015flemek amac\u0131 ile kurulan \u00f6rg\u00fct i\u00e7erisinde yer almak, g\u00f6revi k\u00f6t\u00fcye kullanmak, resmi belgede sahtecilik, resmi belgede yalan beyan” su\u00e7lamalar\u0131 y\u00f6neltildi. 18 May\u0131s’ta \u0130stanbul 10. Asliye Ceza Mahkemesi’nde g\u00f6r\u00fclecek 2007\/75E No’lu dava dosyas\u0131nda ayr\u0131ca 37 \u015firket \u00e7al\u0131\u015fan\u0131 san\u0131k olarak g\u00f6sterildi.<\/p>\n\n\n\n\n
<\/td>\n<\/tr>\n
“\u00c7ete” olu\u015fturmak su\u00e7lamas\u0131yla a\u00e7\u0131lan dava gerek\u00e7esindeki “kamuyu zarara u\u011fratma” su\u00e7uyla ifade edilen ithal ila\u00e7larda uygulanan referans fiyat sistemi. Bu sisteme g\u00f6re T\u00fcrkiye’ye girecek ila\u00e7lara Fransa, \u0130talya, \u0130spanya, Yunanistan ve Portekiz aras\u0131ndaki en d\u00fc\u015f\u00fck fiyat bi\u00e7iliyor. Ancak iddialara g\u00f6re ad\u0131 ge\u00e7en 30 firma bu s\u00fcre\u00e7te en ucuz fiyat\u0131 vermedi ve kamuya y\u00fcksek fiyattan sat\u0131\u015f yapt\u0131. Su\u00e7lamalar\u0131n kayna\u011f\u0131nda ise SSK ve Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’na y\u00fcksek fiyatla ila\u00e7 satt\u0131\u011f\u0131 iddia edilen Roche ila\u00e7 firmas\u0131na y\u00f6nelik incelemeler yat\u0131yor. Ba\u015fbakanl\u0131k Tefti\u015f Kurulu Roche hakk\u0131nda inceleme y\u00fcr\u00fct\u00fcrken 29 firman\u0131n daha devlete usuls\u00fcz olarak y\u00fcksek fiyatla ila\u00e7 satt\u0131\u011f\u0131n\u0131 belirledi. Kurulun durumu bir raporla Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’na iletmesiyle beraber ikinci bir inceleme ba\u015flat\u0131ld\u0131. Bakanl\u0131k m\u00fcfetti\u015flerinin incelemesi sonucunda da 30 ila\u00e7 firmas\u0131n\u0131n ithal etti\u011fi 209 de\u011fi\u015fik ilac\u0131 Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’n\u0131n belirledi\u011fi fiyatlar\u0131n \u00e7ok \u00fczerinde fiyatlarla devlet kurumlar\u0131na satt\u0131\u011f\u0131 ortaya kondu. Bakanl\u0131k daha sonra 113 sayfal\u0131k bir raporla \u0130stanbul Cumhuriyet Ba\u015fsavc\u0131l\u0131\u011f\u0131’na su\u00e7 duyurusu yapt\u0131. Savc\u0131l\u0131\u011f\u0131n yakla\u015f\u0131k bir y\u0131ld\u0131r s\u00fcrd\u00fcrd\u00fc\u011f\u00fc soru\u015fturma ise ge\u00e7en hafta sonu\u00e7land\u0131. \u0130stanbul 10. A\u011f\u0131r Ceza Mahkemesi’nce dava dosyas\u0131 onayland\u0131 ve duru\u015fma tarihi 18 May\u0131s 2007 olarak belirlendi. Konuyla ilgili olarak ila\u00e7 \u015firketleri ve Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 dava s\u00fcrecini etkilememek ad\u0131na a\u00e7\u0131klama yapm\u0131yor.<\/p>\n

\u0130LA\u00c7LARIN \u0130THAL\u0130 TEHL\u0130KEYE G\u0130REB\u0130L\u0130R
4 ilac\u0131yla san\u0131klar aras\u0131nda yer alan Abdi \u0130brahim \u0130la\u00e7 firmas\u0131n\u0131n Genel M\u00fcd\u00fcr\u00fc Erman Atasoy ise bu iddialar\u0131n daha \u00f6nceden ortaya at\u0131ld\u0131\u011f\u0131n\u0131 ve bakanl\u0131kla yapt\u0131klar\u0131 g\u00f6r\u00fc\u015fmelerde sorunu \u00e7\u00f6zd\u00fcklerini belirtti. Atasoy iddialar\u0131n davaya d\u00f6n\u00fc\u015fme s\u00fcrecini de \u015f\u00f6yle anlatt\u0131: “Bu iddialar ortaya at\u0131ld\u0131\u011f\u0131nda Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’n\u0131n ilgili birimleri inceleme yapt\u0131. Bizden belgelerimizi istediler. Sonunda sorunun \u00e7\u00f6z\u00fcld\u00fc\u011f\u00fcn\u00fc ancak denetleme kurulu taraf\u0131ndan ortaya at\u0131lan bir mesele oldu\u011fu i\u00e7in son karar\u0131 savc\u0131l\u0131\u011fa b\u0131rakacaklar\u0131n\u0131 s\u00f6ylediler. Bunun \u00fczerine savc\u0131l\u0131k da davay\u0131 mahkemeye sevk etmeyi ve son karar\u0131 h\u00e2kimlere b\u0131rakmay\u0131 uygun g\u00f6rd\u00fc.” Atasoy, dava s\u00fcrecindeki iddialar hakk\u0131nda daha fazla yorum yapmazken olumsuz bir sonu\u00e7 al\u0131nsa bile ila\u00e7lar\u0131n ithalinde bir sorun ya\u015fanmayaca\u011f\u0131n\u0131 ifade ediyor.
Di\u011fer taraftan T\u00fcrk Tabipleri Birli\u011fi \u0130la\u00e7 Dan\u0131\u015fma Kurulu’ndan Prof. Ersin Yar\u0131\u015f ise ihale kanununa muhalefet eden firmalara daha sonraki kamu ihalelerine kat\u0131lmama yapt\u0131r\u0131m\u0131 getirildi\u011fini hat\u0131rlatt\u0131. “S\u00f6z konusu ila\u00e7lar patent korumas\u0131 dahilinde ise temininde zorluklar ya\u015fanabilir” diyen Yar\u0131\u015f, yine de ba\u015fka \u015firketler \u00fczerinden ithalat yapma y\u00f6ntemiyle sorunun \u00e7\u00f6z\u00fclebilece\u011fine i\u015faret etti. <\/p>\n

ROCHE GER\u0130 \u00d6DEME DI\u015eINA ATILMI\u015eTI
2004 y\u0131l\u0131nda ad\u0131 SSK ve Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’na y\u00fcksek fiyattan ila\u00e7 satma su\u00e7lamalar\u0131na kar\u0131\u015fan Roche’a “kamuyu zarara u\u011fratmak” gerek\u00e7esiyle benzer bir dava a\u00e7\u0131lm\u0131\u015ft\u0131. SSK’ya fahi\u015f fiyatla ila\u00e7 sat\u0131\u015f\u0131yla ilgili olarak eski Roche Genel M\u00fcd\u00fcr\u00fc Faruk Y\u00f6neyman’\u0131n da aralar\u0131nda bulundu\u011fu 17 san\u0131kl\u0131 dava s\u00fcrerken Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 Tefti\u015f Kurulu raporunda, firman\u0131n 1 milyon 400 bin YTL’lik kamu zarar\u0131na yol a\u00e7t\u0131\u011f\u0131n\u0131 ileri s\u00fcrd\u00fc. Bu s\u00fcre zarf\u0131nda firman\u0131n Neupogen adl\u0131 kanser ilac\u0131 devlet geri \u00f6deme listesinden \u00e7\u0131kar\u0131ld\u0131. Kamu ihalelerine bir daha kat\u0131lamama riskiyle kar\u015f\u0131 kar\u015f\u0131ya kalan firma bu s\u00fcrede y\u00f6netim kadrosunu tamamen de\u011fi\u015ftirdi. Daha sonra Roche T\u00fcrkiye Genel M\u00fcd\u00fcr\u00fc George Hadjiev, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’na s\u00f6z konusu miktar\u0131 \u00f6deyerek yol a\u00e7t\u0131klar\u0131 zarar\u0131 tazmin ettiklerini a\u00e7\u0131klad\u0131. Ancak \u015fimdiki davada Roche d\u0131\u015f\u0131ndaki 29 \u015firketin Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 ile benzer bir tazminat anla\u015fmas\u0131 bulunmuyor. <\/p>\n

ROCHE DEVLET \u0130LE ANLA\u015eMI\u015eTI
2004’te devlete y\u00fcksek fiyattan ila\u00e7 satt\u0131\u011f\u0131 gerek\u00e7esiyle Roche’a dava a\u00e7\u0131ld\u0131.
Roche eski Genel M\u00fcd\u00fcr\u00fc Faruk Y\u00f6neyman ve 17 san\u0131k hakk\u0131nda dava a\u00e7\u0131ld\u0131.
Firman\u0131n, devleti 1 milyon 400 bin YTL’lik zarara u\u011fratt\u0131\u011f\u0131 a\u00e7\u0131kland\u0131.
Devlet, Roche’un Neupogen adl\u0131 kanser ilac\u0131n\u0131 geri \u00f6deme listesinden \u00e7\u0131kard\u0131.
Kamu ihalelerine girmeme riskiyle kar\u015f\u0131 kar\u015f\u0131ya kalan Roche y\u00f6netim kadrosunu de\u011fi\u015ftirdi.
Roche, Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131’na s\u00f6z konusu miktar\u0131 \u00f6deyerek zarar\u0131 giderdiklerini a\u00e7\u0131klad\u0131. <\/p>\n

SANIK OLARAK YARGILANACAK \u0130LA\u00c7 \u015e\u0130RKETLER\u0130
– Abdi \u0130brahim,
– Abbott
– Adeka
– Alcon
– Astra Zeneca
– Aventis Pharma
– Bayer
– Boehringering,
– Bristol Mayers SQ
– Erkin
– Fako
– Gen,
– Glaxo Smith Kline
– G\u00fcrel
– Lilly
– Lundbeck
– Merck Sharp Dohme
– Novartis
– Novo Nordisk
– Opakim
– Organon
– Pfizer
– Pharmacia
– Roche
– Sanofi -s\u0130NTEL
– Santa Farma
– Schering Alman
– Schering Plough
– Servier
– Solvay <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

30 \u0130LA\u00c7 \u015e\u0130RKET\u0130 \u00c7ETE SU\u00c7LAMASIYLA SANIK SANDALYES\u0130NDE \u0130stanbul Cumhuriyet Ba\u015fsavc\u0131l\u0131\u011f\u0131 aralar\u0131nda Roche, Abdi \u0130brahim, Bayer, Glaxo Smith Klein ve Pfizer’\u0131n...<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3264","post","type-post","status-publish","format-standard","hentry","category-ced"],"aioseo_notices":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[],"_links":{"self":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/3264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3264"}],"version-history":[{"count":0,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=\/wp\/v2\/posts\/3264\/revisions"}],"wp:attachment":[{"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3264"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.ced.org.tr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}